A phase I study of sunitinib plus bevacizumab in advanced solid tumors. - Wikidata - wikimedia - TriplyDB

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

http://www.wikidata.org/entity/Q33386345

about

Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.New ways to successfully target tumor vasculature in ovarian cancer.Adrenocortical carcinoma: the management of metastatic disease.Targeting angiogenesis in metastatic breast cancer A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109 A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.Safety profile of new anticancer drugs.Sunitinib for the management of advanced renal cell carcinoma.Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.VB-111 for cancer.Axitinib in the treatment of metastatic renal cell carcinoma.Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.Safety and feasibility of targeted agent combinations in solid tumours.The potential of sunitinib as a therapy in ovarian cancer.The emerging quest for the optimal angiostatic combination therapy.Emerging therapeutic approaches in renal cell carcinoma.Sunitinib in kidney cancer: 10 years of experience and development.A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.The bevacizumab experience in advanced renal cell carcinoma Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.Angiogenesis inhibitors in the treatment of prostate cancer Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells

P2860

Q29012696-3299AFE5-346A-4D8D-BC2A-91F37DEA000D Q33415397-1F711013-E111-418A-914C-F5D720EC215E Q33803564-315CEF20-A342-4BAA-98EF-0C83BB04A25A Q34056295-E3AB4786-144D-4F41-AABC-C9AB0DF2AAF2 Q34356881-7F4D376F-AF2D-4E2F-8D8E-37E5A95F1D87 Q34417804-8C436F5B-9F6E-49F4-A97C-A275CDF3859B Q34627163-B80A9C0A-B8E0-45B8-944F-F45400EEABA5 Q34627828-174F12BF-D1A7-456A-925F-9E2C71CFAD6B Q35626845-712A8833-BFE3-44F0-A3FD-F79CA0B9F6FE Q35928220-95542E3F-72A9-4947-A000-CD7A96C8EF40 Q36081865-15A4BAE0-7D79-4741-9917-B7A8602556B1 Q36182795-10C5E31F-64E5-4BA4-9A02-CF6C0636E0C9 Q37166383-FFAA15C0-E91C-479C-BA36-CEBA4A693D32 Q37474683-F6F440AA-45D8-4E14-A466-F70602DAEB20 Q37602900-BA6531EC-9672-49FF-8A3A-1618790ADF5B Q37696502-795B303F-337F-42B6-B78D-9674AC3F9245 Q37705402-37C4267A-B7F9-4CBC-B56C-DA70D4023DC0 Q37752357-D11EF002-B053-4DF5-B285-EFFD0E62A92A Q37941051-C2D306CB-56D5-4373-9064-DEBF50C8AD3F Q37951599-3C27EB46-B281-4922-B4B2-28B8B0B31002 Q37957052-07FBD959-27D9-4C45-8C49-D1B3530510E1 Q37963823-D85621E1-75A6-4F56-ABC3-566C06717A8C Q38077440-7A648894-B9C7-4536-9960-DAFF1895310D Q38144166-0D24778B-ACAA-4E28-BC9F-F7B058DB9858 Q38268453-741E2BC7-0ECA-4398-ACE3-D4BADF9929F7 Q38587958-2119B2F6-6C28-4B2E-9722-0A740B6AC423 Q39038214-ED67A012-8F91-41E5-AE44-151C260A893A Q39532016-29A08AEE-DCD1-47CA-A5D7-02060ABE0634 Q41431404-C7A41C34-E4F9-4846-8FE4-182B87CAE910 Q41899102-FE0392F1-91F5-4333-B3D8-819A620BEB31 Q52670846-E23CDB6E-21D5-4961-A9A7-B48D52792276 Q57139434-7DE30FAA-46AE-4F4D-81AA-2AA6386B6A3C Q58790703-CF508827-1FB4-4898-9453-C7A771264D9C

P2860

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

http://www.wikidata.org/entity/Q33386345

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

@ast

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

@en

type

label

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

@ast

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

@en

prefLabel

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

@ast

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

@en

P1433

Q33386345-F506E547-56B1-4F7A-8D0C-AF397E0C7351

P1476

Q33386345-47E338BF-7F55-4DBA-B746-19DC57ADF863

P2093

Q33386345-0DA03A31-A1A2-4FB2-8A60-17AF530A352B

Q33386345-0F78919A-8B7F-4952-8403-9096F76D923E

Q33386345-1D47122C-FCC3-48C1-90EA-252BE13AA3F6

Q33386345-2BEE0233-B169-4251-9736-E3E6F579C126

Q33386345-2CE70E29-614F-4B79-92A3-EFF8F4620522

Q33386345-30B7E245-CB08-42B2-8C8D-BCA45CA8DB54

Q33386345-34DAD264-038F-4BB3-A298-8B8C760F1264

Q33386345-39033892-8B8A-48AF-8A4D-9EDE324E39DE

Q33386345-647EC7EF-B6F9-4EF6-AB2B-5CB5342BEFDE

Q33386345-8C26333C-4F35-4432-8766-386C9F05497B

P2860

Q33386345-07A71D01-DB95-4C9E-B28F-20475DD74B9D

Q33386345-0BE578A3-7E8B-48C3-B0CC-8ADB3EF283C3

Q33386345-17BD1AD1-7871-44F1-A521-59E74B3FF9CB

Q33386345-1DF5C221-EDE6-4713-985F-F4ABBE75CB8E

Q33386345-22D0D99B-0F3B-468F-8B09-8A5DE5D23171

Q33386345-2489C954-C877-4058-8346-7D87431857A9

Q33386345-43F83A3D-C568-4103-93CC-2B25DC900B92

Q33386345-69853DF4-71AB-4F5C-AE36-25552B4D7B4F

Q33386345-7489DED6-08F3-47C8-8756-BA17520ED18F

Q33386345-7B0735D5-C3E6-44ED-9EE0-3CCF3BCD5E50

P304

Q33386345-507E611D-389F-4646-A8EB-4CBCEFCD3D6F

P31

Q33386345-7A78C86F-FA3D-4F71-AC1A-D20ABC6C5BA1

P356

Q33386345-A832E403-068B-4C50-8022-2759D52B242F

P407

Q33386345-BF142BA3-E98E-4FFF-A44A-059AD8B7D738

P433

Q33386345-1ECF7DFB-8848-4C14-9573-1F0BCCFEA107

P478

Q33386345-96F0D024-E617-45C6-9C3C-149963A098F6

P577

Q33386345-8F239CA4-8656-40B7-B55C-C65A334A7A67

P5875

Q33386345-493B432D-D122-44E9-B4C1-F7D27A0FF7D6

P698

Q33386345-AFE89C0E-7134-4416-BC51-CD565E6B1C90

P921

Q33386345-33F57CCD-7821-49C2-9410-B6F5CE946D32

P932

Q33386345-3D127A3E-CC55-4B7C-980B-C4EA842FE557

P356

1078-0432.CCR-09-0717

P1433

Clinical Cancer Research

P1476

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

@en

P2093

Afshin Dolwati

http://www.w3.org/2001/XMLSchema#string

Allison Tyler

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Ernest Borden

http://www.w3.org/2001/XMLSchema#string

G Thomas Budd

http://www.w3.org/2001/XMLSchema#string

Helen X Chen

http://www.w3.org/2001/XMLSchema#string

Jorge A Garcia

http://www.w3.org/2001/XMLSchema#string

Joseph Bokar

http://www.w3.org/2001/XMLSchema#string

Kristi Beatty

http://www.w3.org/2001/XMLSchema#string

Matthew M Cooney

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

P304

6277-6283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-0717

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26830662

http://www.w3.org/2001/XMLSchema#string

P698

19773375

http://www.w3.org/2001/XMLSchema#string

P921

P932

2756318

http://www.w3.org/2001/XMLSchema#string